StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report sent to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
Bellerophon Therapeutics stock opened at $0.01 on Monday. The stock has a market capitalization of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.02. The stock’s 50 day moving average price is $0.02 and its two-hundred day moving average price is $0.03.
Bellerophon Therapeutics Announces Dividend
The business also recently declared a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were paid a $0.019 dividend. This represents a yield of 117.8%. The ex-dividend date of this dividend was Thursday, December 19th.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to trade using analyst ratings
- 3 Steel Stocks Soaring After Tariff Announcements
- How to Capture the Benefits of Dividend Increases
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
